Alexion Pharmaceuticals, Inc. (ALXN)

Lifshitz & Miller announces investigation on behalf of ALXN investors concerning whether ALXN violated federal securities laws by issuing false and misleading statements concerning its sales practices and revenues from Soliris.

If you are an ALXN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at